ISTI LOGO
Towards a new dawn
×

img Acces sibility Controls

Research Projects Banner

Research Projects

Synthesis and evaluation of novel dual GSK-3β/HDAC inhibitor as an anti-Alzheimer agent

Implementing Organization

National Institute of Pharmaceutical Education and Research, Raebareli
Principal Investigator
Dr. Abha Sharma
Associate Professor
|
National Institute of Pharmaceutical Education and Research, Raebareli

About

A dual classical GSK-3β/epigenetic HDAC6 inhibitor is designed using a multi-target strategy for modulating Alzheimer's disease (AD) targets. The pyrimidone-based series of derivatives will be synthesized using four multistep schemes. The proposed molecules will undergo enzymatic assays, toxicity studies, acute toxicity, memory and cognitive improvement evaluation, and biochemical evaluation. Only one international research study is available.

Related Research

View All
Funding Organization
Funding Organization
Science and Engineering Research Board (SERB), New Delhi
Quick Information
Area of Research
Life Sciences & Biotechnology
Focus Area
Pharmaceuticals, Neurology
Start Year
2023
End Year
2025
Sanction Amount
₹ 37.31 L
Status
Completed
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
N/A
Startup (If Any)
00
No. of Patents
Filed :00
Grant :00
arrowtop